Alterations of p63 and p73 in human cancers

Sub-Cellular Biochemistry

Volumn 85, Issue , 2014, Pages 17-40

  Inoue, Kazushi ^a   Fry, Elizabeth A ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Alteration; Cancer; Knockout; Mouse; Overexpression; p63; p73; Splicing

Indexed keywords

MUS;

CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; KNOCKOUT MOUSE; MOUSE; NEOPLASM; RNA SPLICING;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NEOPLASMS; NUCLEAR PROTEINS; RNA SPLICING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84922393635     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-9211-0_2     Document Type: Article

References (132)

1. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923, Review.
2. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737, Review.
3. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137: 413-431, Review.
4. Green DR, Chipuk JE (2006) p53 and metabolism: inside the TIGAR. Cell 126(1): 30-32, Review.
5. Ruflni A, Tucci P, Celardo I, Melino G (2013) Senescence and aging: the critical roles of p53. Oncogene 32(43): 5129-5143, Review.
6. Xu Y (2008) Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27(25): 3501-3507.
7. Lai D, Visser-Grieve S, Yang X (2012) Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 32(4): 361-374.
8. Frezza C, Martins CP (2012) From tumor prevention to therapy: empowering p53 tofight back. Drug Resist Updat 15(5-6): 258-267.
9. Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo KF, Rait A, Chang EH (2013) Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21(5): 1096-1103.
10. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90(4): 809-819.
11. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2(3): 305-316.
12. Murray-Zmijewski F, Lane DP, Bourdon JC (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13(6): 962-972, Review.
13. Collavin L, Lunardi A, Del Sal G (2010) p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 17(6): 901-911.
14. Schultz J, Ponting CP, Hofmann K, Bork P (1997) SAM as a protein interaction domain involved in developmental regulation. Protein Sci 6(1): 249-253.
15. Thanos CD, Bowie JU (1999) p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci 8(8): 1708-1710.
16. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, Darimont BD, Duijf PH, Van Bokhoven H, McKeon F, Dötsch V (2002) A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 22(24): 8601-8611.
17. Moll UM, Slade N (2004) p63 and p73: roles in development and tumor formation. Mol Cancer Res 2(7): 371-386, From tumor prevention to therapy: empowering p53 tofight back. Review.
18. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19(18): 2122-2137, Epub 2005 Aug 30. Review.
19. Courtois S, Caron de Fromentel C, Hainaut P (2004) p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23(3): 631-638, Review.
20. Chi SW, Ayed A, Arrowsmith CH (1999) Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J 18(16): 4438-4445.
21. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188(9): 1763-1768.
22. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398(6729): 708-713.
23. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deflcient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366): 215-221.
24. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4(1): 1-7.
25. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985): 1233-1238.
26. Malkin D (1993) p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 66(2): 83-92, Review.
27. Strong LC, Williams WR, Tainsky MA (1992) The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 135(2): 190-199, Review.
28. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, Kim MS, Wu G, Nomoto S, Trink B, Sidransky D (2005) Differential recognition of response elements determines target gene speciflcity for p53 and p63. Mol Cell Biol 25(14): 6077-6089.
29. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA (2002) REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 10(5): 995-1005.
30. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y, Tokino T (2002) The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 277(1): 719-724, Epub 2001 Oct 18.
31. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A (2002) Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-speciflc target element within the Delta Np73 promoter. Mol Cell Biol 22(8): 2575-2585.
32. Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB (2013) BRCA1 is a key regulator of breast differentiation through activation of Notch signaling with implications for anti-endocrine treatment of breast cancers. Nucleic Acids Res 41(18): 8601-8614.
33. Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55 kD protein. Genes Dev 8: 1235-1246.
34. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
35. Deb SP (2003) Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 1(14): 1009-1016, Review.
36. Popowicz GM, Czarna A, Holak TA (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7: 2441-2443.
37. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303.
38. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
39. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R et al (2004) Ampliflcation of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835-5843.
40. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL (2008) Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15: 841-848.
41. Okamoto K, Taya Y, Nakagama H (2009) Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett 583: 2710-2714.
42. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, Cox LS, Poon RY (1999) MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 9(15): 829-832.
43. Zdzalik M, Pustelny K, Kedracka-Krok S, Huben K, Pecak A, Wladyka B, Jankowski S, Dubin A, Potempa J, Dubin G (2010) Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle 9(22): 4584-4591.
44. Kojima T, Ikawa Y, Katoh I (2001) Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. Biochem Biophys Res Commun 281: 1170-1175.
45. Little NA, Jochemsen AG (2001) Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 20: 4576-4580.
46. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K et al (2001) MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 490: 202-208.
47. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G (2002) The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 277: 2674-2681.
48. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR (2002) Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323: 491-501.
49. Burge S, Teufel DP, Townsley FM, Freund SM, Bycroft M, Fersht AR (2009) Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation. Proc Natl Acad Sci U S A 106: 3142-3147.
50. Mavinahalli JN, Madhumalar A, Beuerman RW, Lane DP, Verma C (2010) Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics 11(Suppl 1): S5. doi: 10. 1186/1471-2164-11-S1-S5.
51. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM, Roop DR, Bradley A, Mills AA (2006) p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 103(22): 8435-8440.
52. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deflcient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404(6773): 99-103.
53. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416(6880): 560-564.
54. Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K (2011) Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol 5: 235-257. doi: 10. 4137/CMO. S7516, Epub 2011 Jul 28. Review.
55. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL (2003) Signiflcance of p63 ampliflcation and overexpression in lung cancer development and prognosis. Cancer Res 63(21): 7113-7121.
56. Flores ER (2007) The roles of p63 in cancer. Cell Cycle 6(3): 300-304, Epub 2007 Feb 3. Review.
57. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL, Biernaskie JA, Sinha S, Prives C, Pevny LH, Miller FD, Flores ER (2009) TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 5(1): 64-75.
58. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Michurina TV, Enikolopov G, Muthuswamy SK, Mills AA (2011) ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 8(2): 164-176.
59. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11(12): 1451-1457.
60. Aberdam D, Gambaro K, Medawar A, Aberdam E, Rostagno P, de la Forest Divonne S, Rouleau M (2007) Embryonic stem cells as a cellular model for neuroectodermal commitment and skin formation. C R Biol 330(6-7): 479-484. Epub 16 Apr 2007 Apr. Review.
61. Medawar A, Virolle T, Rostagno P, de la Forest-Divonne S, Gambaro K, Rouleau M, Aberdam D (2008) DeltaNp63 is essential for epidermal commitment of embryonic stem cells. PLoS One 3(10): e3441.
62. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest DS, Van Bokhoven H, Candi E, Melino G, Aberdam D (2011) ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 18(5): 887-896.
63. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Ruflni A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, Mak TW (2008) TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22(19): 2677-2691.
64. Wilhelm MT, Ruflni A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD, Mak TW (2010) Isoform-speciflc p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 24(6): 549-560.
65. Zhu J, Jiang J, Zhou W, Chen X (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58(22): 5061-5065.
66. Dohn M, Zhang S, Chen X (2001) p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20(25): 3193-3205.
67. Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in tumorigenesis. Nat Rev Cancer 2(8): 605-615, Review.
68. Melino G (2011) p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 18(9): 1487-1499, Review.
69. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH (1999) p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274(26): 18709-18714.
70. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, Hügli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8(12): 1213-1223.
71. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM (2002) Transactivation-deflcient DeltaTA-p73 acts as an oncogene. Cancer Res 62(13): 3598-3602.
72. Chan WM, Siu WY, Lau A, Poon RY (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24(8): 3536-3551.
73. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K, Harris CC (1999) Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18(22): 3415-3421.
74. Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D, Nakagawara A (1999) p73 at chromosome 1p36. 3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18(4): 1061-1066.
75. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68(4): 820-823.
76. Zaika AI, El-Rifai W (2006) The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ 13(6): 935-940, Review.
77. Park BJ, Lee SJ, Kim JI, Lee CH, Chang SG, Park JH et al (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60: 3370-3374.
78. Grisanzio C, Signoretti S (2008) p63 in prostate biology and pathology. J Cell Biochem 103: 1354-1368.
79. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH et al (2012) Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 109: 15312-15317.
80. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9(15): 5501-5507.
81. Sniezek JC, Matheny KE, Burkey BB, Netterville JL, Pietenpol JA (2002) Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg 126(6): 598-601.
82. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA (2004) Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 114(12): 2063-2072.
83. Ebrahimi M, Wahlin YB, Coates PJ, Sjöström B, Nylander K (2006) Decreased expression of p63 in oral lichen planus and graft-vs.-host disease associated with oral inflammation. J Oral Pathol Med 35(1): 46-50.
84. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D (2000) AIS is an oncogene amplifled in squamous cell carcinoma. Proc Natl Acad Sci U S A 97(10): 5462-5467.
85. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression proflles in human normal and tumor tissues. Clin Cancer Res 8(2): 494-501.
86. Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Caliò A, Eccher A, Parolini C, Iannucci A, Gilioli E, Pedron S, Massari F, Tortora G, Borze I, Knuutila S, Gobbo S, Santo A, Tondulli L, Calabrò F, Martignoni G, Chilosi M (2012) True 3q chromosomal ampliflcation in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. PLoS One 7(12): e49689.
87. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW (2006) Tumorspeciflc p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66(19): 9362-9368.
88. King KE, Weinberg WC (2007) p63: deflning roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol Carcinog 46(8): 716-724.
89. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA (2005) High-resolution genomic proflles of human lung cancer. Proc Natl Acad Sci U S A 102(27): 9625-9630.
90. Tonon G, Brennan C, Protopopov A, Maulik G, Feng B, Zhang Y, Khatry DB, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Wong KK, Depinho RA (2005) Common and contrasting genomic proflles among the major human lung cancer subtypes. Cold Spring Harb Symp Quant Biol 70: 11-24.
91. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S (2001) A simple speciflc pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 61(10): 4122-4129.
92. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD, Crum CP (2001) Histologic and immunophenotypic classiflcation of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 32(5): 479-486.
93. Hu H, Xia SH, Li AD, Xu X, Cai Y, Han YL, Wei F, Chen BS, Huang XP, Han YS, Zhang JW, Zhang X, Wu M, Wang MR (2002) Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer 102(6): 580-583.
94. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A (2002) Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 99(1): 22-28.
95. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, Sjöström B, Dahlqvist A, Coates PJ (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198(4): 417-427.
96. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K (2002) p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9(3): 216-219.
97. Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC (2003) Distribution of p63, a novel myoepithelial marker, infine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 99(3): 172-179.
98. Koker MM, Kleer CG (2004) p63 expression in breast cancer: a highly sensitive and speciflc marker of metaplastic carcinoma. Am J Surg Pathol 28(11): 1506-1512.
99. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2): 264-271.
100. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9(1): 45-56.
101. Zangen R, Ratovitski E, Sidransky D (2005) DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4(10): 1313-1315, Epub 2005 Oct 1.
102. Danilov AV, Neupane D, Nagaraja AS, Feofanova EV, Humphries LA, DiRenzo J, Korc M (2011) DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One 6(10): e26815.
103. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically deflned subset of primary breast cancers. J Clin Invest 117(5): 1370-1380.
104. Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, Ono K, Morita M, Yasumoto K (2005) A lack of prognostic signiflcance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer 50(1): 67-73.
105. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K (2006) Expression of the p53 family in lung cancer. Anticancer Res 26(3A): 1785-1790.
106. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA (2006) Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66(15): 7589-7597.
107. Helton ES, Zhu J, Chen X (2006) The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 281(5): 2533-2542.
108. Celardo I, Grespi F, Antonov A, Bernassola F, Garabadgiu AV, Melino G, Amelio I (2013) Caspase-1 is a novel target of p63 in tumor suppression. Cell Death Dis 4: e645.
109. Han S, Semba S, Abe T, Makino N, Furukawa T, Fukushige S, Takahashi H, Sakurada A, Sato M, Shiiba K, Matsuno S, Nimura Y, Nakagawara A, Horii A (1999) Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol 25(2): 194-198.
110. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36. 33 in human lung cancers. Cancer Res 58(7): 1380-1383.
111. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM (2004) Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64(7): 2449-2460.
112. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F (2006) DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24(5): 805-815, Epub 2005 Dec 27.
113. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F, Koscielny S, Bosq J, Bénard J, Ahomadegbe JC (2008) Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle 7(11): 1587-1596.
114. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K (2004) Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10(20): 6905-6911.
115. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ, Karayan-Tapon L (2006) Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 95(8): 1062-1069.
116. Castillo J, Goñi S, Latasa MU, Perugorría MJ, Calvo A, Muntané J, Bioulac-Sage P, Balabaud C, Prieto J, Avila MA, Berasain C (2009) Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 137(5): 1805-15. e1-4.
117. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59(14): 3352-3356.
118. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP (1999) Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94(3): 1113-1120.
119. Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW (2010) BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res 70(18): 7155-7165.
120. Alexandrova EM, Moll UM (2012) Role of p53 family members' p73 and p63 in human hematological malignancies. Leuk Lymphoma 53(11): 2116-2129.
121. Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN, Zoumpourlis V, Field JK, Liloglou T (2011) Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett 300(1): 79-86.
122. Guan M, Chen Y (2005) Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol 58(11): 1175-1179.
123. Díaz R, González-Sancho JM, Soldevilla B, Silva J, García JM, García V, Peña C, Herrera M, Gómez I, Bonilla F, Domínguez G (2010) Differential regulation of TP73 isoforms by 1α, 25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas. Genes Chromosomes Cancer 49(12): 1135-1142.
124. Quon KC, Berns A (2001) Haplo-insufflciency? Let me count the ways. Genes Dev 15(22): 2917-2921, Review.
125. Berger AH, Pandolfi PP (2011) Haplo-insufflciency: a driving force in cancer. J Pathol 223(2): 137-146. doi: 10. 1002/path. 2800, Epub 2010 Oct 29. Review.
126. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ (2001) Dmp1 is haplo-insufflcient for tumor suppression and modifles the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 15(22): 2934-2939.
127. Inoue K, Mallakin A, Frazier DP (2007) Dmp1 and tumor suppression. Oncogene 26(30): 4329-4335, Epub 2007 Jan 22. Review.
128. Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB Jr, Willingham MC, Inoue K (2007) Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 12(4): 381-394.
129. Sugiyama T, Frazier DP, Taneja P, Kendig RD, Morgan RL, Matise LA, Lagedrost SJ, Inoue K (2008) Signal transduction involving the dmp1 transcription factor and its alteration in human cancer. Clin Med Oncol 2: 209-219, Epub 2008 Apr 1.
130. Taneja P, Maglic D, Kai F, Sugiyama T, Kendig RD, Frazier DP, Willingham MC, Inoue K (2010) Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res 70(22): 9084-9094.
131. Zhu S, Mott RT, Fry EA, Taneja P, Kulik G, Sui G, Inoue K (2013) Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer. Am J Pathol 183(4): 1339-1350.
132. Fry EA, Taneja P, Maglic D, Zhu S, Sui G, Inoue K (2013) Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One 8(10): e77870. doi: 10. 1371/journal. pone. 0077870.